Bishoyi AK, Roham PH, Rachineni K, Save S, Hazari MA, Sharma S, et al. Human islet amyloid polypeptide (hIAPP)-a curse in type II diabetes mellitus: insights from structure and toxicity studies. Biol Chem. 2021;402(2):133–53.
Article CAS PubMed Google Scholar
El Saghir A, Farrugia G, Vassallo N. The human islet amyloid polypeptide in protein misfolding disorders: mechanisms of aggregation and interaction with biomembranes. Chem Phys Lipids. 2021;234:105010.
Tang Y, Zhang D, Zhang Y, Liu Y, Gong X, Chang Y, et al. Introduction and fundamentals of human islet amyloid polypeptide inhibitors. ACS Appl Bio Mater. 2020;3(12):8286–308.
Article CAS PubMed Google Scholar
Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011;91(3):795–826.
Article CAS PubMed Google Scholar
Ling W, Huang Y-M, Qiao Y-C, Zhang X-X, Zhao H-L. Human amylin: from pathology to physiology and pharmacology. Curr Protein Pept Sci. 2019;20(9):944–57.
Article CAS PubMed Google Scholar
Cohen AS, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature. 1959;183(4669):1202–3.
Article CAS PubMed Google Scholar
Pearse A, Ewen S, Polak J. The genesis of apudamyloid in endocrine polypeptide tumours: histochemical distinction from immunamyloid. Virchows Archiv B. 1972;10:93–107.
Westermark P, Wernstedt C, Wilander E, Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun. 1986;140(3):827–31.
Article CAS PubMed Google Scholar
Cooper G, Willis A, Clark A, Turner R, Sim R, Reid K. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proceedings of the National Academy of Sciences. 1987;84(23):8628-32.
Cooper G, Leighton B, Dimitriadis G, Parry-Billings M, Kowalchuk J, Howland K et al. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proceedings of the National Academy of Sciences. 1988;85(20):7763-6.
Hirai Y. In-vivo like studies of the h-IAPP amyloid precursors using Dielectric Relaxation. WORCESTER POLYTECHNIC INSTITUTE; 2013.
Park YJ. The role of Fas-mediated apoptotic pathway in amyloid-induced beta-cell death. University of British Columbia; 2015.
Zou X, Ouyang H, Yu T, Chen X, Pang D, Tang X, et al. Preparation of a new type 2 diabetic miniature pig model via the CRISPR/Cas9 system. Cell Death Dis. 2019;10(11):823.
Article PubMed PubMed Central Google Scholar
Bhowmick DC. The molecular mechanisms of Stress-Induced Amylin turnover in pancreatic Beta cell. The George Washington University; 2018.
Gilead S, Wolfenson H, Gazit E. Molecular mapping of the recognition interface between the islet amyloid polypeptide and insulin. Angew Chem. 2006;118(39):6626–30.
Dubey R, Patil K, Dantu SC, Sardesai DM, Bhatia P, Malik N, et al. Azadirachtin inhibits amyloid formation, disaggregates pre-formed fibrils and protects pancreatic β-cells from human islet amyloid polypeptide/amylin-induced cytotoxicity. Biochem J. 2019;476(5):889–907.
Article CAS PubMed Google Scholar
Riahi Y, Wikstrom JD, Bachar-Wikstrom E, Polin N, Zucker H, Lee M-S, et al. Autophagy is a major regulator of beta cell insulin homeostasis. Diabetologia. 2016;59:1480–91.
Article CAS PubMed PubMed Central Google Scholar
Leissring MA, González-Casimiro CM, Merino B, Suire CN, Perdomo G. Targeting insulin-degrading enzyme in insulin clearance. Int J Mol Sci. 2021;22(5):2235.
Article CAS PubMed PubMed Central Google Scholar
AlAnazi FH, Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Ogaly HA et al. Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena. J Diabetes.n/a(n/a).
Guillemain G, Lacapere J-J, Khemtemourian L. Targeting hIAPP fibrillation: A new paradigm to prevent β-cell death? Biochimica et Biophysica Acta (BBA)-Biomembranes. 2022:184002.
Sevcuka A, White K, Terry C. Factors that contribute to hiapp amyloidosis in type 2 diabetes mellitus. Life. 2022;12(4):583.
Article CAS PubMed PubMed Central Google Scholar
Rasheed HA, Al-Kuraishy HM, Al-Gareeb AI, Hussien NR, Al-Nami MS. Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: bane or Boon. J Adv Pharm Technol Res. 2019;10(4):163.
Article PubMed PubMed Central Google Scholar
Al-Kuraishy HM, Al-Gareeb AI, Waheed HJ, Al-Maiahy TJ. Differential effect of metformin and/or glyburide on apelin serum levels in patients with type 2 diabetes mellitus: concepts and clinical practice. J Adv Pharm Technol Res. 2018;9(3):80.
Article CAS PubMed PubMed Central Google Scholar
Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Nadwa EH, Albogami SM et al. Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure. J Diabetes. 2022; n/a(n/a)
Abdul-Hadi MH, Naji MT, Shams HA, Sami OM, Al-Harchan NA-A, Al-Kuraishy HM, et al. Oxidative stress injury and glucolipotoxicity in type 2 diabetes mellitus: the potential role of metformin and sitagliptin. Biomedical and Biotechnology Research Journal (BBRJ). 2020;4(2):166.
Al-Nami MS, Al-Kuraishy HM, Al-Gareeb AI, Al-Mamoori F. Metabolic profile and prolactin serum levels in men with type 2 diabetes mellitus: old-new rubric. Int J Crit Illn Inj Sci. 2019;9(3):120.
Article PubMed PubMed Central Google Scholar
Mulder H, Gebre-Medhin S, Betsholtz C, Sundler F, Ahrén B. Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes. Am J Physiology-Endocrinology Metabolism. 2000;278(4):E684–E91.
Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, et al. Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1991;34:129–32.
Article CAS PubMed Google Scholar
Bennett RG, Duckworth WC, Hamel FG. Degradation of amylin by insulin-degrading enzyme. J Biol Chem. 2000;275(47):36621–5.
Article CAS PubMed Google Scholar
Bennett RG, Hamel FG, Duckworth WC. An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes. 2003;52(9):2315–20.
Article CAS PubMed Google Scholar
Maianti JP, McFedries A, Foda ZH, Kleiner RE, Du XQ, Leissring MA, et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 2014;511(7507):94–8.
Article CAS PubMed PubMed Central Google Scholar
Tang W-J. Targeting insulin-degrading enzyme to treat type 2 diabetes mellitus. Trends Endocrinol Metab. 2016;27(1):24–34.
Article CAS PubMed Google Scholar
Bortoletto AS, Graham WV, Trout G, Bonito-Oliva A, Kazmi MA, Gong J et al. Human Islet Amyloid Polypeptide (hIAPP) Protofibril‐Specific Antibodies for Detection and Treatment of Type 2 Diabetes. Adv Sci. 2022:2202342.
Clark A, Nilsson M. Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes? Diabetologia. 2004;47:157–69.
Article CAS PubMed Google Scholar
Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes. 1999;48(2):241–53.
Article CAS PubMed Google Scholar
Westermark P. Amyloid and polypeptide hormones: what is their interrelationship? Amyloid. 1994;1(1):47–60.
Bram Y, Frydman-Marom A, Yanai I, Gilead S, Shaltiel-Karyo R, Amdursky N, et al. Apoptosis induced by islet amyloid polypeptide soluble oligomers is neutralized by diabetes-associated specific antibodies. Sci Rep. 2014;4(1):4267.
Article PubMed PubMed Central Google Scholar
Ma L, Yang C, Huang L, Chen Y, Li Y, Cheng C, et al. Glycated insulin exacerbates the cytotoxicity of human islet amyloid polypeptides: a vicious cycle in type 2 diabetes. ACS Chem Biol. 2019;14(3):486–96.
Article CAS PubMed Google Scholar
Hoenig M, Hall G, Ferguson D, Jordan K, Henson M, Johnson K, et al. A feline model of experimentally induced islet amyloidosis. Am J Pathol. 2000;157(6):2143–50.
Article CAS PubMed PubMed Central Google Scholar
Soty M, Visa M, Soriano S, del Carmen Carmona M, Nadal Á, Novials A. Involvement of ATP-sensitive potassium (KATP) channels in the loss of beta-cell function induced by human islet amyloid polypeptide. J Biol Chem. 2011;286(47):40857–66.
Article CAS PubMed PubMed Central Google Scholar
Hussien NR, Al-Naimi MS, Rasheed HA, Al-Kuraishy HM, Al-Gareeb AI. Sulfonylurea and neuroprotection: the bright side of the moon. J Adv Pharm Technol Res. 2018;9(4):120.
Article CAS PubMed PubMed Central Google Scholar
Xu J, Jin L, Chen J, Zhang R, Zhang H, Li Y, et al. Common variants in genes involved in islet amyloid polypeptide (IAPP) processing and the degradation pathway are associated with T2DM risk: a chinese population study. Diabetes Res Clin Pract. 2022;185:109235.
Article CAS PubMed Google Scholar
Jeong HR, An SSA. Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus. Clin Interv Aging. 2015:1873–9.
Fernández MS. Human IAPP amyloidogenic properties and pancreatic β-cell death. Cell Calcium. 2014;56(5):416–27.
留言 (0)